NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update
TORONTO and HAIFA, Israel, June 20, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ('NurExone' or the 'Company'), a biotech company developing exosome-based therapies for central nervous system injuries, announced today that it has been accepted into the HealthTech Hub ('HTH') Accelerator Program. Based in Boston, Massachusetts, home to more than 1,000 biotech companies1, HTH is operated by the Advanced Regenerative Manufacturing Institute ('ARMI') and its BioFabUSA initiative.
NurExone's acceptance into the prestigious HTH Accelerator Program will support the Company's expansion into the U.S. market following the establishment of Exo-top Inc. ('Exo-TOP'), the Company's wholly owned U.S. subsidiary dedicated to GMP-compliant exosome manufacturing for clinical development and commercial scale-up.
HTH, co-led by ARMI and Mass General Brigham, is a competitive accelerator program supported by the U.S. Department of Health and Human Services and Israel's Ministry of Health. The HTH Accelerator Program selects a limited number of innovative companies each year to help them validate U.S. clinical relevance, strengthen commercialization strategies, and build meaningful collaborations with key stakeholders across the U.S. HealthTech landscape. The program is funded by HTH at no cost to participants.
Dr. Lior Shaltiel, CEO of NurExone, commented: 'The HTH Acceleration Program offers the kind of U.S.-based insight and guidance needed at this stage of our growth. As we establish Exo-TOP to manufacture clinical-grade exosomes in the U.S., the HTH will help us sharpen our regulatory and scale-up strategies and pursue meaningful commercial collaboration opportunities. This is a timely and strategic opportunity to accelerate our commercialization pathway in the world's largest healthcare market 2 .'
NurExone's participation in the HTH Accelerator Program is expected to enhance its visibility within the U.S. regenerative medicine ecosystem and to support its mission to bring novel exosome-based therapeutics to patients with unmet needs.
Omnibus Plan Approval
The Company is pleased to announce that, further to its press release dated June 4, 2025, at the Company's annual general and special meeting held on June 18, 2025 (the 'Meeting'), disinterested shareholders ratified and approved the amended and restated omnibus incentive plan (the 'Omnibus Plan'), a copy of which is available under the Company's SEDAR+ profile at www.sedarplus.ca.
The Omnibus Plan is a hybrid plan that provides flexibility to grant-equity incentive awards in the form of stock options ('Options'), restricted shares ('Restricted Shares') and restricted share units ('RSUs').
The Omnibus Plan is a hybrid 10% rolling and 10% fixed share-based compensation plan that amends and restates the Company's previous equity incentive plan approved by shareholders on June 4, 2024 (the 'Previous Plan'). The Previous Plan was a 20% fixed share-based compensation plan whereby the maximum number of common shares in the capital of the Company ('Common Shares') reserved for issuance was set at 13,166,085, representing 20% of the issued and outstanding Common Shares as of the effective date.
The Omnibus Plan now includes (i) a 10% 'rolling' Option component that shall not exceed 10% of the Company's total issued and outstanding Common Shares from time to time; and (ii) a 10% fixed component permitting up to 7,800,781 RSUs and Restricted Shares in the aggregate.
Additionally, the Omnibus Plan was amended to increase the number of securities issuable to insiders of the Company. The Previous Plan provided, that unless approved by disinterested shareholders, (i) the maximum number of securities issuable to insiders collectively would not exceed 10% of the Company's securities at any time and (ii) the maximum number of securities issuable to insiders collectively in any twelve-month period would not exceed 10% of the Company's total issued and outstanding securities as at the date any award was granted to an insider. Now, the Omnibus Plan provides the following that (i) the maximum number of the Company's securities issuable to insiders collectively shall not exceed 20% of the Company's total issued and outstanding Common Shares at any point in time and (ii) the maximum number of the Company's securities issuable to insiders collectively, in any 12-month period, when combined with all of the Company's other share compensation arrangements, shall not exceed 20% of the Company's total issued and outstanding securities, calculated as at the date any award is granted or issued to any insider.
RSU Grants
In addition, the Company announced that it has granted an aggregate of 1,125,000 RSUs to certain officers and directors of the Company pursuant to the terms and conditions of the Omnibus Plan. Each RSU vests on the one-year anniversary of the grant date and may be settled, upon their vesting, into one Common Share. The RSUs and underlying Common Shares are subject to the Exchange Hold Period (as such term is defined under the policies of the TSX Venture Exchange ('TSXV')).
About NurExone
NurExone Biologic Inc. is a TSXV, OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multi-billion-dollar marketsi. Regulatory milestones, including obtaining the Orphan Drug Designation, facilitates the roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top Inc., a U.S. subsidiary, to anchor its North American activity and growth strategy.
For additional information and a brief interview, please watch Who is NurExone?, visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.
For more information, please contact:
Dr. Lior ShaltielChief Executive Officer and DirectorPhone: +972-52-4803034
Email: [email protected]
Dr. Eva Reuter
Investor Relations – GermanyPhone: +49-69-1532-5857
Email: [email protected]
Allele Capital Partners
Investor Relations – U.S.Phone: +1 978-857-5075
Email: [email protected]
FORWARD-LOOKING STATEMENTS
This press release contains certain 'forward-looking statements' that reflect the Company's current expectations and projections about its future results. Wherever possible, words such as 'may', 'will', 'should', 'could', 'expect', 'plan', 'intend', 'anticipate', 'believe', 'estimate', 'predict' or 'potential' or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to: the; the Company's acceptance into the prestigious HTH Accelerator Program will support the Company's expansion into the U.S. market; the Company's participation in the HTH Accelerator Program is expected to enhance its visibility within the U.S. regenerative medicine ecosystem and support its mission as discussed herein; each RSU will be settled into one Common Share; and the NurExone platform technology offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications, including recovery of optic nerve function and overall visual health.
These statements reflect management's current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including: the Company's acceptance into the prestigious HTH Accelerator Program will allow it to support the Company's expansion into the U.S. market; the Company's participation in the HTH Accelerator Program will give the Company the ability to enhance its visibility within the U.S. regenerative medicine ecosystem and support its mission as discussed herein; each RSU will be settled into one Common Share; and the NurExone platform technology offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications, including recovery of optic nerve function and overall visual health
Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to: the Company's early stage of development; lack of revenues to date; government regulation; market acceptance for its products; rapid technological change; dependence on key personnel; dependence on the Company's strategic partners; the fact that preclinical drug development is uncertain, and the drug product candidates of the Company may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of the Company; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the inability to obtain or maintain regulatory approval of the drug product candidates of the Company; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of the Company; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected or impacted by unforeseen issues; the inability to obtain adequate financing; the inability to obtain or maintain intellectual property protection for the drug product candidates of the Company; risks that the Company's intellectual property and technology won't have the intended impact on the Company and/or its business; the Company's inability to carry out its pre-clinical trials and realize upon the stated benefits of the pre-clinical trials; the inability of the Company to realize on the benefits of exosomes; the inability of the Company to produce and/or supply exosomes for a wide range of applications; the inability of the Company's products to be used for patient treatment; there not being broader adoption in the field and/or cell therapy applications; the inability of the Company to fulfill its intended future plans and expectations; there not being growing clinical demand for innovative treatments in spinal cord, optic nerve, and/or other therapeutic areas; the Company's inability to realize upon the stated potential for exosome-loaded drugs in regenerating or repairing damaged nerves; the Company's inability to maintain its ongoing commitment to using its ExoTherapy platform to advance the field of regenerative medicine and/or cell therapy applications; the Company's inability to expand into further studies; the Company will not receive all required regulatory approvals; the Company will not have clinical and/or commercial breakthroughs in regenerative medicine; the Company will be unable to enhance its presence in key markets; the NurExone platform technology not offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications; the Company will not realize its future development plans, operational initiatives, and strategic objectives; the Company will not advance its therapeutic programs and clinical milestones; the Company will not engage with regulatory agencies; the Company's acceptance into the prestigious HTH Accelerator Program will not support the Company's expansion into the U.S. market; the Company's participation in the HTH Accelerator Program will not enhance its visibility within the U.S. regenerative medicine ecosystem and will not support its mission as discussed herein; each RSU will not be settled into one Common Share; and the risks discussed under the heading 'Risk Factors' on pages 44 to 51 of the Company's Annual Information Form dated August 27, 2024, a copy of which is available under the Company's SEDAR+ profile at www.sedarplus.ca . These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.
Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
i Spinal cord injury, Glaucoma
1 https://www.epmscientific.com
2 https://www.hbmhealthcare.com
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Flowers Foods Lowers Fiscal 2025 Outlook as Second-Quarter Sales Miss Views
Flowers Foods (FLO) lowered its full-year outlook on Friday as the packaged bakery food producer rep Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Osisko Development Closes US$203 Million Private Placement Financing
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES MONTREAL, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Osisko Development Corp. (NYSE: ODV, TSXV: ODV) ("Osisko Development" or the "Company") is pleased to announce the successful closing of its previously announced private placement of 99,065,330 units of the Company (each, a "Unit") at a price of US$2.05 per Unit (the "Issue Price") for aggregate gross proceeds of approximately US$203 million (the "Offering"). The Offering is comprised of (i) a "bought deal" brokered private placement of 58,560,000 Units at the Issue Price for aggregate gross proceeds of approximately US$120 million (the "Brokered Offering"), and (ii) a non-brokered private placement of 40,505,330 Units at the Issue Price for aggregate gross proceeds of approximately US$83 million (the "Non-Brokered Offering"). The Non-Brokered Offering includes an approximate US$75 million subscription by Double Zero Capital LP ("Double Zero"), a Delaware investment firm, representing approximately 15.4% of the issued and outstanding common shares of the Company immediately following the closing of the Offering, on a non-diluted basis (refer to "Early Warning Disclosure of Double Zero" below). Sean Roosen, Chairman and CEO, commented: "We are very pleased to complete this offering and to welcome Double Zero as a new long-term strategic shareholder of Osisko Development, as we continue to build positive momentum toward a construction decision at Cariboo. This US$203 million financing represents another strong endorsement of the Cariboo Gold Project and our team, following the recent US$450 million project financing with Appian. Together, these milestones underscore Osisko Development's unique value proposition and we believe puts us on solid footing to secure funding for the construction of the permitted Cariboo Gold Project." The Brokered Offering was led by BMO Capital Markets and RBC Capital Markets, as joint lead managers and joint bookrunners, and Cantor Fitzgerald Canada Corporation, as co-lead underwriter, on behalf of a syndicate of underwriters including National Bank Financial Inc. and Ventum Financial Corp. (collectively, the "Underwriters"). Each Unit consists of one common share of the Company (each, a "Common Share") and one-half of one Common Share purchase warrant (each whole Common Share purchase warrant, a "Warrant"). Each whole Warrant shall entitle the holder thereof to purchase one Common Share (each, a "Warrant Share"), at a price of US$2.56 per Warrant Share on or prior to August 15, 2027 (being, 24 months from the date of issuance), subject to acceleration. At any time following the 15-month anniversary of the closing date, if the closing price of the Common Shares on either the TSX Venture Exchange (the "TSXV") or the New York Stock Exchange exceeds the exercise price for 20 or more consecutive trading days, the Company may, within 10 days following such occurrence, deliver a notice to the holders thereof accelerating the expiry date of the Warrants to a date that is 30 days after the date of such notice. The Company intends to use the net proceeds of the Offering to fund the broadly distributed equity portion of the capital required to construct the Cariboo Gold Project and for general corporate purposes. The Company believes that the net proceeds of the Offering, together with the net proceeds of the US$450 million project loan credit facility with Appian Capital Advisory Limited announced on July 21, 2025, plus indications of interest from commodity traders seeking high-quality concentrate off-take, and other potential financing arrangements, will provide sufficient funding to construct the Cariboo Gold Project. In connection with the Offering, the Underwriters were paid a cash commission equal to 4.5% of the aggregate gross proceeds of the Brokered Offering. In addition, in connection with the subscription by Double Zero, the Company paid Double Zero an investment fee equal to 4.0% of the gross proceeds from the subscription, which investment fee was settled in Common Shares. All securities issued under the Offering (including the Common Shares issued to Double Zero in satisfaction of the investment fee payable to Double Zero) will be subject to a Canadian hold period expiring four months and one day from the date of issue pursuant to applicable Canadian securities laws. The Offering and investment fee remain subject to final acceptance of the TSXV. Insider Participation Certain insiders of the Company have subscribed for 628,000 Units under the Offering for aggregate gross proceeds of US$1,287,400. Each subscription by an "insider" is considered to be a "related party transaction" for the purposes of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company did not file a material change report more than 21 days before the expected closing date of the Offering as the details of the Offering and the participation therein by each "related party" of the Company were not settled until shortly prior to the closing of the Offering, and the Company wished to close the Offering on an expedited basis for sound business reasons. The Company is relying on exemptions from the formal valuation and minority shareholder approval requirements available under MI 61-101. The Company is exempt from the formal valuation requirement in section 5.4 of MI 61-101 in reliance on section 5.5(a) of MI 61-101 as the fair market value of the transaction, insofar as it involves interested parties, is not more than 25% of the Company's market capitalization. Additionally, the Company is exempt from minority shareholder approval requirement in section 5.6 of MI 61-101 in reliance on section 5.7(1)(a) of MI 61-101 as the fair market value of the transaction, insofar as it involves interested parties, is not more than 25% of the Company's market capitalization. Early Warning Disclosure of Double Zero In connection with its subscription in the Non-Brokered Offering, Double Zero acquired ownership and control, directly and indirectly, of 36,600,000 Common Shares and 18,300,000 Warrants (which Warrants are subject to a blocker provision). Prior to the Offering, Double Zero did not hold any securities of the Company. After giving effect to the Offering and the investment fee payment (as settled in 1,464,000 Common Shares), Double Zero holds an aggregate of 38,064,000 Common Shares and 18,300,000 Warrants, representing approximately 16.0% of the issued and outstanding Common Shares on a non-diluted basis (approximately 21.9% on a partially-diluted basis, assuming full exercise of the Warrants held by Double Zero). The Warrants issued to Double Zero are subject to a blocker provision, such that Double Zero may not exercise any Warrants that would result in it holding (directly or indirectly) over 19.9% of the issued and outstanding Common Shares (after giving effect to such exercise), unless requisite shareholder, stock exchange and regulatory approvals have been obtained. An early warning report in respect of the Company will be filed by Double Zero with applicable Canadian securities regulatory authorities and will be available on SEDAR+ ( under the Company's issuer profile. To obtain copies of the early warning report once filed by Double Zero, please contact Melanie Cole of Aird & Berlis LLP, counsel to Double Zero, email: mcole@ and telephone: 416.865.4638. The Common Shares and Warrants were acquired by Double Zero for investment purposes. Depending on market conditions and other factors, Double Zero may, from time to time, acquire additional Common Shares, Common Share purchase warrants or other securities of the Company or dispose of some or all of the securities in the Company that it owns at such time. Double Zero and the Company entered into an investor rights agreement effective as of August 15, 2025 (the "Investor Rights Agreement") pursuant to which, among other things, the Company agreed to provide Double Zero with rights to nominate one director to the board of directors of the Company, customary pre-emptive rights and top-up rights in respect of certain acquisitions. In addition, pursuant to the terms of the Investor Rights Agreement, Double Zero has agreed to provide certain voting support to the Company. A copy of the Investor Rights Agreement will be filed on SEDAR+ ( under the Company's issuer profile. The securities offered have not been registered under the U.S. Securities Act of 1933, as amended (the ""), and may not be offered or sold in the United States or to "U.S. Persons" (as such terms are defined in Regulation S under the U.S. Securities Act) absent registration under the U.S. Securities Act and all applicable U.S. state securities laws or in compliance with applicable exemptions therefrom. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful. ABOUT OSISKO DEVELOPMENT CORP. Osisko Development Corp. is a continental North American gold development company focused on past-producing mining camps located in mining friendly jurisdictions with district scale potential. The Company's objective is to become an intermediate gold producer by advancing its flagship permitted 100%-owned Cariboo Gold Project, located in central B.C., Canada. Its project pipeline is complemented by the Tintic Project in the historic East Tintic mining district in Utah, U.S.A., and the San Antonio Gold Project in Sonora, Mexico—brownfield properties with significant exploration potential, extensive historical mining data, access to existing infrastructure and skilled labour. The Company's strategy is to develop attractive, long-life, socially and environmentally responsible mining assets, while minimizing exposure to development risk and growing mineral resources. For further information, visit our website at or contact: Sean Roosen Philip Rabenok Chairman and CEO Vice President, Investor Relations Email: sroosen@ Email: prabenok@ Tel: +1 (514) 940-0685 Tel: +1 (437) 423-3644 CAUTION REGARDING FORWARD-LOOKING STATEMENTS This news release contains "forward-looking information" (within the meaning of applicable Canadian securities laws) and "forward- looking statements" (within the meaning of the U.S. Private Securities Litigation Reform Act of 1995). Such statements or information are identified with words such as "anticipate", "believe", "expect", "plan", "intend", "potential", "estimate", "propose", "project", "outlook", "foresee" or similar words suggesting future outcomes or statements regarding any potential outcome. Such statements in this news release may include, without limitation, statements pertaining to the use of the net proceeds from the Offering, the availability and use of proceeds of the credit facility (including the ability and timing to satisfy conditions precedents to subsequent draws under the credit facility (if at all)), the other financing arrangements that the Company is negotiating (including, the indications of interest, the type of financing arrangements, the size and quantum of such financing arrangements and the ability and timing to reach a definitive agreement in respect of these indications of interests (if at all)), the expectations regarding the Company's capital requirements to advance the Cariboo Gold Project to production, the ability of the Company to raise or arrangement for the remaining funding required to complete the construction of the Cariboo Gold Project, the timing and ability of the Company to make a final investment decision in respect of the Cariboo Gold Project, the ability to obtain the final acceptance of the TSXV and/or the New York Stock Exchange, and the Company's strategy and objectives relating to the Cariboo Gold Project as well as its other projects. Such forward-looking information or statements are based on a number of risks, uncertainties and assumptions which may cause actual results or other expectations to differ materially from those anticipated and which may prove to be incorrect. Actual results could differ materially due to a number of factors, including, without limitation, satisfying the requirements of the TSXV and the New York Stock Exchange (if at all), the availability of the credit facility (including compliance with covenants under the credit facility or satisfaction of conditions to any subsequent draws or advances under the credit facility), the accuracy of estimated costs and risks of cost overruns and additional capital requirements in connection with advancing the Cariboo Gold Project to production, risks related to exploration, development and operation of the Cariboo Gold Project, the ability of the Company to reach a definitive agreement or obtain any funding from other financing arrangements (including, the terms and structure and timing thereof (if at all)), general economic and market conditions and business conditions in the mining industry, fluctuations in commodity and currency exchange rates, changes in regulatory framework and applicable laws, as well as those risks and factors as disclosed in the Company's most recent annual information form, financial statement and management's discussion and analysis as well as other public filings on SEDAR+ ( Although the Company believes that the expectations reflected in the forward-looking information or statements are reasonable, prospective investors in the Company securities should not place undue reliance on forward-looking statements because the Company can provide no assurance that such expectations will prove to be correct. Forward-looking information and statements contained in this news release are as of the date of this news release and the Company assumes no obligation to update or revise this forward-looking information and statements except as required by law. The information provided herein as it relates to Double Zero has been furnished by Double Zero. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained in to access your portfolio
Business Wire
2 hours ago
- Business Wire
FUTR Surpasses 1,000,000 Transactions and USD$380 Million in Payments Volume With FinWise Bank
TORONTO--(BUSINESS WIRE)--The FUTR Corporation (TSXV: FTRC) (OTCQB: FTRCF) ("FUTR" or the "Company"), a consumer-centric platform for data valuation and monetization is pleased to announce a major operational milestone, passing 1,000,000 transactions and USD$380 million in payment transaction volume using FinWise Bank's payment rails. The platform has processed more than $3 billion in payments for nearly 300,000 users through automated cash flow and loan management. Since March 2024, these transactions have leveraged FinWise Bank's payment services, including multiple cost-efficient payment rails. FUTR also maintains monthly deposits at FinWise from transiting payments as part of the overall relationship. As FUTR expands into new consumer markets and introduces the AI Agent App, it expects significant growth in transaction volume, processed dollars, and deposits on its banking partner platforms. With new partners and a deepening of the FinWise partnership, FUTR also anticipates greater payment automation. Leveraging FinWise's efficient and cost-effective platform, FUTR earns convenience fees on transactions and basis points on transiting deposits. 'This milestone demonstrates consumers' strong trust in FUTR to deliver real savings and convenience with our automated cash management platform coupled with smart payment rails,' said Mindy Bruns, Chief Business Officer at FUTR. 'A major part of this value is access to solid infrastructure from FinWise. We're preparing for substantial growth in users and features in the months ahead.' 'We appreciate that FUTR recognizes our vision and the value of our payments platforms,' stated Robert Keil, SVP and Chief Fintech Officer at FinWise Bank. 'We are pleased with the customer migration and see a lot of value in FUTR's consumer-focused services. This partnership with FUTR also gives FinWise the opportunity to generate lower-cost deposits.' About The FUTR Corporation FUTR's AI Agent App is focused on putting money back in consumer's wallets through a unique data monetization rewards system, personalized offers as well as agent-driven smart payment management. The FUTR AI Agent App will allow Enterprises to get rewarded for contributing consented Consumer data to the Agent and allow Brands to leverage this data to improve personalization and customer acquisition. About FinWise Bank Corp. FinWise provides Banking and Payments solutions to fintech brands. Its existing Strategic Program Lending business, conducted through scalable API-driven infrastructure, powers deposit, lending and payments programs for leading fintech brands. As part of Strategic Program Lending, FinWise also provides a Credit Enhanced Balance Sheet Program, which addresses the challenges that lending and card programs face diversifying their funding sources and managing capital efficiency. In addition, FinWise manages other Lending programs such as SBA 7(a), Owner Occupied Commercial Real Estate, and Leasing, which provide flexibility for disciplined balance sheet growth. The Company is also expanding and diversifying its business model by incorporating Payments (MoneyRails ™) and BIN Sponsorship offerings. Through its compliance oversight and risk management-first culture, the Company is well positioned to guide fintechs through a rigorous process to facilitate regulatory compliance. Forward-Looking Statements This news release may contain forward-looking statements (within the meaning of applicable securities laws) which reflect the Company's current expectations regarding future events. Forward-looking statements are identified by words such as 'believe', 'anticipate', 'project', 'expect', 'intend', 'plan', 'will', 'may', 'estimate' and other similar expressions. These statements are based on the Company's expectations, estimates, forecasts, and projections and include, without limitation, statements regarding the future success of the Company's business. The forward-looking statements in this news release are based on certain assumptions. The forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. A number of factors could cause actual results to differ materially from the results discussed in the forward-looking statements. Readers, therefore, should not place undue reliance on any such forward-looking statements. Further, these forward-looking statements are made as of the date of this news release and, except as expressly required by applicable law, the Company assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
